Skip to main content
Clinical Trials/NCT04985500
NCT04985500
Active, not recruiting
Early Phase 1

Erector Spinae Plane Block vs. Pecto-intercostal Fascial Plane Block vs. Control for Sternotomy: A Prospective Randomized Trial

Icahn School of Medicine at Mount Sinai1 site in 1 country225 target enrollmentJuly 9, 2021

Overview

Phase
Early Phase 1
Intervention
ESP block
Conditions
Cardiac Surgery
Sponsor
Icahn School of Medicine at Mount Sinai
Enrollment
225
Locations
1
Primary Endpoint
Opioid Consumption during first 48 hours post-op
Status
Active, not recruiting
Last Updated
9 months ago

Overview

Brief Summary

This is a randomized study. The purpose of this study is to evaluate the effect of post-surgical pain control of two types of peripheral nerve blocks, specifically erector spinal plane (ESP) block and pecto-intercostal fascial (PIF) plane block.

90 subjects, from 18-85 years of age, undergoing cardiac surgery with median sternal incision will be enrolled at Mount Sinai Morningside Hospital Center. Study participation will last from the time of pre-operative evaluation to 72 hours after surgery. Subjects will be randomly assigned to receive 1 of the 3 different regimens at the beginning of surgery. Opioid consumption and pain scores after surgery will be evaluated. Though unlikely, risks include systemic absorption of local anesthetic, which can result in both central nervous system and cardiac toxicity.

Registry
clinicaltrials.gov
Start Date
July 9, 2021
End Date
December 31, 2025
Last Updated
9 months ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ali Nima Shariat

Assistant Professor

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

Inclusion Criteria

  • Adults 18-85 years old
  • Scheduled to undergo cardiac procedures involving sternotomy
  • All genders

Exclusion Criteria

  • ASA class V
  • Urgent or emergent surgery
  • Contraindications to administration of local anesthesia (e.g. local anesthetic allergy)
  • History of substance abuse or chronic opioid use
  • Patient refusal or inability to consent

Arms & Interventions

ESP group

Patient will receive ESP block with ultrasound guidance the transverse process of the vertebra at T7 is visualized and 20 mL of 0.25% bupivacaine will be injected between the transverse process and the erector spinae muscle on each side using a 21-gauge block needle.

Intervention: ESP block

ESP group

Patient will receive ESP block with ultrasound guidance the transverse process of the vertebra at T7 is visualized and 20 mL of 0.25% bupivacaine will be injected between the transverse process and the erector spinae muscle on each side using a 21-gauge block needle.

Intervention: Ultrasound

ESP group

Patient will receive ESP block with ultrasound guidance the transverse process of the vertebra at T7 is visualized and 20 mL of 0.25% bupivacaine will be injected between the transverse process and the erector spinae muscle on each side using a 21-gauge block needle.

Intervention: Bupivacain

PIF group

Patient will receive PIF block after intubation with ultrasound placed 1-2 cm lateral to the sternal border and the pectoralis major and external intercostal muscles are visualized at the level of ribs 3-4 where 10 mL of 0.25% bupivacaine will be injected on each side using a 21-gauge block needle.

Intervention: PIF block

PIF group

Patient will receive PIF block after intubation with ultrasound placed 1-2 cm lateral to the sternal border and the pectoralis major and external intercostal muscles are visualized at the level of ribs 3-4 where 10 mL of 0.25% bupivacaine will be injected on each side using a 21-gauge block needle.

Intervention: Ultrasound

PIF group

Patient will receive PIF block after intubation with ultrasound placed 1-2 cm lateral to the sternal border and the pectoralis major and external intercostal muscles are visualized at the level of ribs 3-4 where 10 mL of 0.25% bupivacaine will be injected on each side using a 21-gauge block needle.

Intervention: Bupivacain

Outcomes

Primary Outcomes

Opioid Consumption during first 48 hours post-op

Time Frame: Post-operative 48 hours

The amount of opioid consumption (in mg IV morphine equivalents) during the first 48 hours post-op in patients undergoing cardiac surgeries with median sternotomy.

Opioid Consumption during first 24 hours post-op

Time Frame: Post-operative 24 hours

The amount of opioid consumption (in mg IV morphine equivalents) during the first 24 hours post-op in patients undergoing cardiac surgeries with median sternotomy.

Opioid Consumption during first 72 hours post-op

Time Frame: Post-operative 72 hours

The amount of opioid consumption (in mg IV morphine equivalents) during the first 72 hours post-op in patients undergoing cardiac surgeries with median sternotomy.

Secondary Outcomes

  • Visual Analogue Score (VAS) Pain Score post-op 48 hours(Post-operative 48 hours)
  • Visual Analogue Score (VAS) Pain Score post-op 72 hours(Post-operative 72 hours)
  • Visual Analogue Score (VAS) Pain Score post-op 24 hours(Post-operative 24 hours)

Study Sites (1)

Loading locations...

Similar Trials